Home » Stocks » NTEC

Intec Pharma Ltd. (NTEC)

Stock Price: $3.89 USD -0.08 (-2.02%)
Updated Mar 8, 2021 1:50 PM EST - Market open
Market Cap 15.67M
Revenue (ttm) n/a
Net Income (ttm) -17.11M
Shares Out 3.95M
EPS (ttm) -6.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 8
Last Price $3.89
Previous Close $3.97
Change ($) -0.08
Change (%) -2.02%
Day's Open 3.97
Day's Range 3.80 - 4.20
Day's Volume 126,894
52-Week Range 2.20 - 15.82

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Pulse2 - 2 months ago

Shares of Intec Pharma Ltd (NASDAQ:NTEC) surged today as it went from $3.46 per share yesterday to a day high of $7.12 -- which imputes a jump of 105.78%. This is why it happened.

InvestorPlace - 2 months ago

Shares of NTEC stock are soaring on Wednesday after Intec Pharma announced a cannabinoid research collaboration with GW Pharma. The post Intec Pharma News: Why NTEC Stock Is on Fire Today appe...

Schaeffers Research - 4 months ago

Welcome back to our weekly series,  Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks last week and we will look ahead at the pot stocks to...

Other stocks mentioned: CGC, APHA, CRON, GWPH, IIPR, VFF, XXII, YCBD
PRNewsWire - 4 months ago

JERUSALEM, Nov. 5, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the third quarter ended September 30, 2020 and provide...

PRNewsWire - 5 months ago

JERUSALEM, Oct. 8, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces it has entered into a new research collaboration agreement with MSD, the tra...

PRNewsWire - 5 months ago

JERUSALEM, Sept. 14, 2020 /PRNewswire/ -- Intec Pharma Ltd.

GlobeNewsWire - 7 months ago

JERUSALEM, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”), today announced that it has entered into a definitive agreement with Aspire Capital ...

PRNewsWire - 7 months ago

JERUSALEM, Aug. 5, 2020 /PRNewswire/ -- Intec Pharma Ltd.

Zacks Investment Research - 9 months ago

Intec Pharma Ltd. (NTEC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research - 9 months ago

Investors need to pay close attention to Intec Pharma (NTEC) stock based on the movements in the options market lately.

PRNewsWire - 9 months ago

JERUSALEM, May 28, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company management will present at the Jefferies Virtual Healthcare...

GlobeNewsWire - 10 months ago

JERUSALEM , May 04, 2020 (GLOBE NEWSWIRE) -- Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”), today announced that it has entered into definitive agreements with several institut...

Investopedia - 1 year ago

The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges.

Other stocks mentioned: ARNA, CARA, CRBP, CRON, GNLN, GWPH, MBII, NBEV, OGI, PMD, SNDL, TLRY, TRPX, VFF, ZYNE
GlobeNewsWire - 1 year ago

JERUSALEM, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announced the pricing of its previously announced underwritten public offering ...

Benzinga - 1 year ago

Micro-cap Intec Pharma Ltd (NASDAQ: NTEC) shares are plummeting on heavy volume Monday following a clinical trial readout from the company.

Market Watch - 1 year ago

Shares of biotech Intec Pharma Ltd. plunged 80% in premarket trade Monday after the company said its late-stage trial of a drug meant to treat symptoms of advanced Parkinson's disease did not ...

About NTEC

Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Pa... [Read more...]

Industry
Biotechnology
Founded
2000
CEO
Jeffrey Meckler
Employees
38
Stock Exchange
NASDAQ
Ticker Symbol
NTEC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Intec Pharma stock is "Buy." The 12-month stock price forecast is 9.00, which is an increase of 131.36% from the latest price.

Price Target
$9.00
(131.36% upside)
Analyst Consensus: Buy